Clinical Trials Logo

Dermatitis, Atopic clinical trials

View clinical trials related to Dermatitis, Atopic.

Filter by:

NCT ID: NCT04612062 Completed - Atopic Dermatitis Clinical Trials

A First-in-Human Study of CEE321 in Adult Subjects

Start date: February 27, 2020
Phase: Phase 1
Study type: Interventional

Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis

NCT ID: NCT04606615 Recruiting - Atopic Dermatitis Clinical Trials

Skin Barrier Abnormalities and Oxidative Stress Response

Start date: October 16, 2020
Phase:
Study type: Observational

This is a prospective, single-site controlled observational study designed to comprehensively determine whether children and adults with atopic dermatitis (AD) and food allergy (FA) have skin abnormalities which distinguish them from children with AD without FA, and non-atopic (NA) controls.

NCT ID: NCT04605094 Terminated - Atopic Dermatitis Clinical Trials

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

Start date: November 12, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.

NCT ID: NCT04599946 Active, not recruiting - Child Development Clinical Trials

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

GIraFFE
Start date: January 8, 2021
Phase: N/A
Study type: Interventional

To determine the relative risk of developing atopic dermatitis in infants fed a study formula based on whole goat milk compared to infants a study formula based on cow milk protein.

NCT ID: NCT04598269 Completed - Atopic Dermatitis Clinical Trials

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Start date: September 30, 2020
Phase: Phase 2
Study type: Interventional

This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of participants with moderate or severe atopic dermatitis (AD).

NCT ID: NCT04587453 Completed - Atopic Dermatitis Clinical Trials

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

ECZTRA 8
Start date: October 27, 2020
Phase: Phase 3
Study type: Interventional

Primary objective: To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, health-related quality of life, and health care resource utilisation compared with placebo in combination with TCS. To assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 16 weeks.

NCT ID: NCT04564755 No longer available - Atopic Dermatitis Clinical Trials

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Start date: n/a
Phase:
Study type: Expanded Access

This is a multi-center, expanded access protocol to provide access to the investigational product, abrocitinib, to adolescent and adult patients with moderate to severe atopic dermatitis who have inadequate treatment options with available and approved medicated topical and systemic therapies and who are otherwise ineligible for participation in clinical studies with abrocitinib.

NCT ID: NCT04562116 Completed - Atopic Dermatitis Clinical Trials

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

Start date: May 24, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderateto- severe atopic dermatitis (AD).

NCT ID: NCT04556461 Completed - Atopic Dermatitis Clinical Trials

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

TraSki
Start date: September 28, 2020
Phase: Phase 2
Study type: Interventional

Effects of tralokinumab treatment of atopic dermatitis on skin barrier function.

NCT ID: NCT04553224 Completed - Atopic Dermatitis Clinical Trials

Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis

Start date: November 12, 2019
Phase: N/A
Study type: Interventional

Atopic dermatitis represents a real challenge in public health as it affects a large percentage of children and adults. Affected individuals must cope with a significant psychosocial burden, in addition to dealing with the medical aspects of the disease. The purpose of this exploratory study is to collect clinical severity AD data, using PO-SCORAD (self-assessment by the subjects), SCORAD evolution, instrumental measurements and treatment follow up of subjects. The future objective is to develop a personalised prediction model of AD flares in order to improve management of AD by more accurate severity evaluations by the subject and the physician. Development of a method of early detection of flares will open new treatment pathways for AD management.